Finley Rebecca S
Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, Philadelphia, PA 19104, USA.
Semin Oncol. 2002 Feb;29(1 Suppl 4):132-8. doi: 10.1053/sonc.2002.31534.
Bone metastases are one of the most common problematic complications of advanced cancers. In addition to causing significant pain, bone metastases often result in fractures and debilitation. Stimulation of osteoclast activity by factors secreted by tumor cells is believed be the primary mechanism of bone destruction. Bisphosphonates inhibit osteoclast-related bone resorption, and have become standard therapy in the treatment of hypercalcemia of malignancy and postmenopausal osteoporosis. More recently, bisphosphonates have been shown to decrease pain and skeletal fractures associated with bone metastases. Structural changes in bisphosphonates influence their relative potency as well as other potentially beneficial effects such as inhibition of tumor growth factors, alteration of adhesion molecules, and apoptosis of tumor cells.
骨转移是晚期癌症最常见的棘手并发症之一。除了引起剧痛外，骨转移还常常导致骨折和身体虚弱。肿瘤细胞分泌的因子刺激破骨细胞活性被认为是骨破坏的主要机制。双膦酸盐抑制破骨细胞相关的骨吸收，已成为治疗恶性肿瘤高钙血症和绝经后骨质疏松症的标准疗法。最近，双膦酸盐已被证明可减轻与骨转移相关的疼痛和骨骼骨折。双膦酸盐的结构变化会影响其相对效力以及其他潜在的有益作用，如抑制肿瘤生长因子、改变黏附分子和诱导肿瘤细胞凋亡。
